

# Timing of Surgery in Iraqi Patients with COVID-19 Infection

Mohammed Rashied Salih, Ghadhfan Abdulmajeed Saeed\* and Aymen Abdulkareem Othman Alrawi

Abu-Graib General Hospital, Baghdad Alkarkh Health Directorate, Ministry of Health/Environment, Baghdad, Iraq

## Abstract

Patients with perioperative COVID-19 infection are at high risk of death and complications postoperatively. Now day, COVID-19 infection in Iraq accounted 1,696,390 cases with 19,087 deaths. A national, single, and observational study that included patients with COVID-19 infection undergoing any type of surgery in Abu-Graib General Hospital, Baghdad Iraq during period from 19 March 2020 to 30 April 2021. Time from the diagnosis of COVID-19 infection to day of surgery was collected as a categorical factor divided into: (a) 0-3 weeks; (b) 4-6 weeks; (c) >6 weeks. Age; sex; American Society of Anesthesiologists (ASA) physical status; cardiac comorbidities; respiratory comorbidities; indication for surgery; surgery grade; and surgical types were documented. A total of 378 patient were included with mean age was 47.89±16.03 years. Females were more than males (65.87% > 34.13%). Approximately, 76.72% of patients belonged within ASA I-II, whereas 23.28% were ASA III-IV. About 19.05% of patients suffered from cardiac comorbidities. 266/378 of patients complained from respiratory comorbidities. Surgery indicated in 35.45% benign conditions, 27.5% obstetrics, 7.65% oncological surgery, and 29.4% traumatic operations. Major operations documented in 205/378 patients. Emergencies surgical intervention done in (176, 46.56%), whereas elective cases were 202/378 (53.44%). In total at operation timing, 80(21.16%) patients had a preoperative COVID-19 diagnosis. The time from COVID-19 diagnosis to surgery was 0–3 weeks in 98 patients (25.93%), 4-6 weeks in 115 patients (30.42%), and >6 weeks in 165 patients (43.65%). The overall postoperative mortality rate was 9.52% (36/378). In regard to PO cardiac complication, there was no significant association in relation to timing before surgery ( $p=0.08$ ). However, the overall cardiac complication was 16.4%. Overall, 44.97% (170/378) of patients developed a PO pulmonary complication within period of follow-up. To our knowledge this is the first study to provide strong data regarding the optimal timing for surgery following COVID-19 infection in Iraq. The optimal timing of surgery after COVID-19 infection was more than 6 wks. We found that risks of PO morbidity and mortality are greatest if patients are operated within 6 wks of diagnosis of COVID-19 infection.

**Keywords:** COVID-19 Infection; Post-Surgery Timing; Cardiac and Respiratory Complications

\***Correspondence to:** Ghadhfan Abdulmajeed Saeed, Abu-Graib General Hospital, Baghdad Alkarkh Health Directorate, Ministry of Health/Environment, Baghdad, Iraq; E-mail: [medicalresearch64@yahoo.com](mailto:medicalresearch64@yahoo.com)

**Citation:** Salih MR, Saeed GA, Alrawi AAO (2021) Timing of Surgery in Iraqi Patients with COVID-19 Infection. *Prensa Med Argent*, Volume 107:4. 339. DOI: <https://doi.org/10.47275/0032-745X-339>

**Received:** August 09, 2021; **Accepted:** August 17, 2021; **Published:** August 23, 2021

## Introduction

Patients with perioperative COVID-19 infection are at high risk of death and pulmonary complications post-surgery [1,2]. Most developing countries as Iraq are likely to have limited access to COVID-19 vaccines because of unwilling of peoples to vaccination [3]. Thus, preoperative COVID-19 infection will stay a challenge for the foreseeable future. Several studies suggest delaying surgery in patients who have experienced respiratory infection in the 4 weeks preceding surgery [4]. However, there is only limited evidence regarding the optimal timing of surgery following COVID-19 infection. A prospective cohort study on patients having surgical for cancer, found that surgery more than 4 weeks after a positive COVID-19 swab was associated with a lower risk of postoperative mortality than earlier surgery [5]. A study in Brazil documented that elective surgery was delayed following the preoperative diagnosis of asymptomatic COVID-19 infection, and the postoperative complication rates were comparable to patients without COVID-19 infection. However, the study did not assess the optimal duration of delay following COVID-19 diagnosis [6].

International clinical guidelines support post-poning non-emergency surgery for patients with preoperative COVID-19 infection, but specific recommendations are conflicting, recommending delays ranging from 1 to 12 weeks [7-9].

The aim of this study was to determine the optimal timing of surgery following COVID-19 infection in Iraq.

## Methods

### Study Design and Setting

This was a national, single, and observational study that included patients with COVID-19 infection undergoing any type of surgery in Abu-Graib General Hospital, Baghdad Iraq during period from 19 March 2020 to 30 April 2021.

### Procedures

Surgery was defined as any procedure that is routinely performed in an operating theatre by a surgeon. Participating hospitals included consecutive patients undergoing elective or emergency surgery for any



indication. Emergency surgery was defined as surgery on an unplanned admission, and elective surgery was defined as surgery on a planned admission [10].

### Participants

Patients were classified as having preoperative SARSCoV-2 infection based on any one of the following criteria:

- Positive RT-PCR nasopharyngeal swab taken before surgery;
- Positive rapid Anti-g test performed before surgery;
- Chest computed tomography (CT) scan performed before surgery showing changes consistent with pneumonitis secondary to COVID-19 infection;
- Positive preoperative IgG or IgM Ab test.

### Data Collection

Time from the diagnosis of COVID-19 infection to day of surgery was collected as a categorical factor divided into: (a) 0–3 wks; (b) 4–6 wks; (c)  $\geq 7$  wks.

The following data was collected for each patient: age; sex; American Society of Anesthesiologists (ASA) physical status (I-IV) [8]; cardiac comorbidities; respiratory comorbidities; indication for surgery (benign disease; oncology; obstetrics; trauma); surgery grade (major/minor); and surgical types (elective/emergency).

### Ethics Approval

All authors declare they have no competing interests. The study was approved by the Abu-Graib General Hospital.

### Statistical Analysis

We implemented standard descriptive statistics and data analysis using IBM SPSS Statistics Software (version 25). All p-values  $< 0.05$  were considered statistically significant. Data are reported as means and standard deviations or medians and percentages of patients for categorical variables. For categorical variables, a chi-squared test was used to test for differences between groups.

### Results

A total of 378 patient (all of them previously had history of COVID-19 infection) were included with mean age was  $47.89 \pm 16.03$  years. Most of patients aged between 41 to 60 years. Females were more than males (65.87%  $>$  34.13%). Approximately, 76.72% of patients belonged within ASA I-II, whereas 23.28% were ASA III-IV. About 19.05% of patients suffered from cardiac comorbidities. 266/378 of patients complained from respiratory comorbidities. Surgery indicated in 35.45% benign conditions, 27.5% obstetrics, 7.65% oncological surgery, and 29.4% traumatic operations. Major operations documented in 205/378 patients, while minor was recorded in 173/378 patients. Emergencies surgical intervention done in (176, 46.56%), whereas elective cases were 202/378 (53.44%). In total at operation timing, 80 (21.16%) patients had a preoperative COVID-19 diagnosis (Table 1).

The time from COVID-19 diagnosis to surgery was 0-3 wks in 98 patients (25.93%) (including 80 cases were positive for COVID-19), 4-6 wks in 115 patients (30.42%), and  $>6$  wks in 165 patients (43.65%) (Table 2).

The overall postoperative mortality rate was 9.52% (36/378). When

**Table 1:** Baseline characteristics of the study (n=378).

Variables		No.	%
Age (years) 47.89±16.03	0-20	24	6.35
	21-40	101	26.72
	41-60	154	40.74
	61-80	78	20.63
	>80	21	5.55
Gender	Male	129	34.13
	Female	249	65.87
ASA	I-II	290	76.72
	III-IV	88	23.28
Cardiac comorbidities	Yes	72	19.05
	No	306	80.95
Respiratory comorbidities	Yes	266	70.4
	No	112	29.6
Surgery indication	Benign	134	35.45
	Obstetrics	104	27.5
	Oncology	29	7.65
	Traumatic	111	29.4
Surgery grade	Major	205	54.23
	Minor	173	45.77
Surgery type	Emergency	176	46.56
	Elective	202	53.44
COVID-19	Positive	80	21.16
	Negative	298	78.84

**Table 2:** Preoperative COVID-19 infection by timing of diagnosis prior to surgery.

Timing (weeks)	No.	%
0-3	98	25.93
4-6	115	30.42
>6	165	43.65

stratified by time from COVID-19 diagnosis to surgery, postoperative mortality rates were as follows: 6.1% (32/98) 0-3 wks; 2.12% (8/115) 4-6 wks; and 1.32% (5/165)  $>6$  wks, with high statistically significant differences ( $p < 0.01$ ). In regard to PO cardiac complication, there was no significant association in three period of timing before surgery ( $p = 0.08$ ). However, the overall cardiac complication was 16.4%. Overall, 44.97% (170/378) of patients developed a P. O. pulmonary complication within period of follow-up of one month (Table 3).

**Table 3:** Mortality and complication in relation to timing of surgery.

Timing (weeks)	Mortality	Cardiac complication	Respiratory complication	No complication
0-3	23 (6.1)	12 (3.18)	53 (14.02)	0
4-6	8 (2.12)	28 (7.4)	52 (13.75)	17 (4.5)
>6	5 (1.32)	22 (5.82)	65 (17.2)	83 (22)
Total	36 (9.52)	62 (16.4)	170 (44.97)	100 (26.5)
P value*	<0.01	0.08	0.055	0.054

### Discussion

This study found that patients operated within 6 weeks of COVID-19 diagnosis were at an increased risk of PO mortality and complications. These risks declined to baseline in patients who underwent surgery  $> 6$  weeks after COVID-19 diagnosis. These findings might consistent across both low-risk (age  $< 70$  years, ASA physical status I-II, minor surgery) and high-risk (age  $\geq 70$  years, ASA physical status III-IV, major surgery) sub-groups. Therefore, surgery should be delayed for at least 6 weeks following COVID-19 infection to reduce the risk of postoperative mortality and complications. In addition, we to those patients may get benefit from a further delay



until their COVID-19 infection resolve. Our findings that preoperative COVID-19 infection increases the risk of postoperative mortality and pulmonary complications is line with previous work [1,2].

The greater timing of this study compared with previous studies [5,6] has enabled > 6 wks to be determined as the optimal cut-off. Whilst cut-offs beyond 7 wks were not formally tested, they are unlikely to offer a significant advantage, since adjusted mortality rates for delay intervals  $\geq 7$  wks were broadly stable [1].

There is a backlog of tens of millions of elective operations that were cancelled during the early phase of the COVID-19 pandemic [11]. This study offers evidence to support the safe restarting of surgery in the context of a rapidly increasing number of people who have survived COVID-19. This study's findings should support informed shared decision-making by anesthetists, surgeons and patients. Decisions tailored for each patient, since the possible advantages of delaying surgery for at least 7 weeks following COVID-19 diagnosis that balanced against the potential risks of delay [12]. For some urgent surgical procedures, such as resection of advanced tumours [13,14], surgeons and patients may decide that the risks of delay are not justified. The timing of elective surgery after recovery from COVID-19 utilizes both symptom- and severity-based categories, which suggested wait times from the date of COVID-19 diagnosis to surgery are as follows: four wks for an asymptomatic patient or recovery from only mild, non-respiratory symptoms; six wks for a symptomatic patient (e.g., cough, dyspnea) who did not require hospitalization; 8-10 wks for a symptomatic patient who is DM, immunocompromised, or hospitalized and 12 wks for a patient who was admitted to an ICU due to COVID-19 infection [8].

Generally, all non-urgent procedures should be delayed until the patient has met criteria for discontinuing isolation and COVID-19 transmission precautions and has entered the recovery phase. Elective surgeries should be performed for patients who have recovered from COVID-19 infection only when the anesthesiologist and surgeon agree jointly to proceed [8].

## Conclusion

To our knowledge this is the first study to provide strong data regarding the optimal timing for surgery following COVID-19 infection in Iraq. The optimal timing of surgery after COVID-19 infection was more than 6 wks. We found that risks of P. O. morbidity and mortality are greatest if patients are operated within 6 wks of diagnosis of COVID-19 infection. Our results suggest that, surgery should be delayed for at least 6 wks following COVID-19 infection, and patients with ongoing COVID-19 from diagnosis may get high benefit from further delay.

## Acknowledgments

Authors wish to acknowledge Dr. Ahmed Alshewered for his helping.

## Disclosure of Conflict of Interest

There was no conflict of interest to be declared.

## References

1. COVID Surg Collaborative (2020) Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS CoV-2 infection: an international cohort study. *Lancet* 396: 27-38. [https://doi.org/10.1016/S0140-6736\(20\)31182-X](https://doi.org/10.1016/S0140-6736(20)31182-X)
2. Jonker PK, Van der Plas WY, Steinkamp PJ, Poelstra R, Emous M, et al. (2021) Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications, and thromboembolic events: a Dutch, multicenter, matched-cohort clinical study. *Surgery* 169: 264-274. <https://doi.org/10.1016/j.surg.2020.09.022>
3. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, et al. (2021) Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. *Lancet* 397: 1023-1034. [https://doi.org/10.1016/S0140-6736\(21\)00306-8](https://doi.org/10.1016/S0140-6736(21)00306-8)
4. Canet J, Gallart L, Gomar C, Paluzie G, Valles J, et al. (2010) Prediction of postoperative pulmonary complications in a population-based surgical cohort. *Anesthesiology* 113: 1338-1350. <https://doi.org/10.1097/ALN.0b013e3181fc6e0a>
5. COVID Surg Collaborative (2020) Delaying surgery for patients with a previous SARS-CoV-2 infection. *Br J Surg* 107: e601-e602. <https://dx.doi.org/10.1002/bjs.12050>
6. Baiocchi G, Aguiar Jr S, Duprat JP, Coimbra FJ, Makkissi FB, et al. Early postoperative outcomes among patients with delayed surgeries after preoperative positive test for SARS-CoV-2: a case-control study from a single institution. *J Surg Oncol* 123: 823-833. <https://doi.org/10.1002/jso.26377>
7. Frydenberg M, Maddern G, Collinson T (2021) Delaying surgery for patients recovering from COVID-19: a rapid review commissioned by RACS. Australia.
8. American Society of Anesthesiologists (2020) ASA and APSF joint statement on elective surgery and anesthesia for patients after COVID-19 infection. United States.
9. European Association for Endoscopic Surgery and other Interventional Techniques (2021) Preoperative testing and screening for elective surgery during the pandemic COVID-19 to re-start surgery. The Netherlands.
10. McCaskie AW (2018) *Bailey & Love's short practice of surgery*. (27th edtn), Taylor and Francis Publishers, New York, United States.
11. COVID Surg Collaborative (2020) Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. *Br J Surg* 107: 1440-1449. <https://doi.org/10.1002/bjs.11746>
12. COVID Surg Collaborative, Global Surg Collaborative (2021) Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. *Anaesthesia* 76: 748-758. <https://doi.org/10.1111/anae.15458>
13. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, et al. (2020) Mortality due to cancer treatment delay: systematic review and meta-analysis. *Br Med J* 371: m4087. <https://doi.org/10.1136/bmj.m4087>
14. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, et al. (2020) The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol* 21: 1023-1034. [https://doi.org/10.1016/S1470-2045\(20\)30388-0](https://doi.org/10.1016/S1470-2045(20)30388-0)